According to the analysis, the number of prostate cancer cases worldwide is likely to double by 2040

Largest research of its kind predicts 85% rise in death rates over same period as more men live longer

The total number of men diagnosed with prostate disease is expected to double to 2.9 million a year by 2040, with annual passes expected to rise by 85%, according to the largest research of its kind.

Prostate disease is now a major cause of death and disability and the most common type of male malignancy in more than 100 countries. Be that as it may, with the aging population and future growth around the world, further research shows a sensational flood of cases and cases over the next 15 years.

Analyzes estimate an increase from 1.4 million a year in 2020 to 2.9 million by 2040, which will mean around 330 men will be permanently told they have the disease.

The total number of passages is expected to increase by 85% over 20 years, from 375,000 in 2020 to just 700,000 by 2040. The actual loss of life is most likely higher, specialists say, due to underdiagnosis and missing information in low and middle wage countries.

 According to the analysis, the number of prostate cancer cases worldwide is likely to double by 2040

The findings were distributed in the Lancet journal as part of its milestone bonus on malignant prostate growth and will be presented at the annual European Relationship of Urology congress in Paris on Saturday.

A teenage population and an expanding future mean that the number of established men living longer is increasing. Since the main risk factors for prostate malignancy — such as age 50 or more and a family history of the disease — are undeniable, experts say it will be difficult to prevent the flood in cases essentially through lifestyle changes or general wellness mediation.

In any case, greater attention to the side effects of the disease, access to test drives, prior analysis and advances in therapies can help reduce weight and save lives, according to the authors of the 40-page report.

"As an ever-increasing number of men across the planet live into middle and advanced age, an increase in the number of cases of malignant prostate growth is inevitable," said Professor Scratch James, lead author of the review. "We realize that this flood of cases is coming, so we really want to start arranging and acting now."

"Evidence-based mediation, for example, has worked on early recognition and training programmes, will help save lives and prevent debilitation from prostate disease for years to come," added James, Professor of Prostate Malignancy Research at the Malignant Growth Organisation. Exploration, London, and a specialist clinical oncologist at the Illustrious Marsden NHS trust.

James said there is a global demand for better than ever ways to test for infection to reduce overdiagnosis and overtreatment while distinguishing previously potentially fatal growths.

In addition, promoting information among men and their groups of traits to look for was key, the report said.

Side effects of prostate disease may include expecting to urinate more and more frequently, often during the evening; expect to rush to the latrine; difficulty starting to urinate; feeling that your bladder has not completely emptied and blood in your urine or semen.

These side effects generally do not mean that you have a malignant prostate growth. Many men's prostates become enlarged over the years due to a condition called benign prostatic hyperplasia. Signs that prostate disease may have spread include gonads, back or bone pain, lack of appetite, and unexpected weight loss.

In addition, the concentrate included a request for more research to be more likely to catch malignant prostate growth in people of color, since most of the research has focused on white men.

Alfred Samuels was 54 years old when he learned in 2012 that he had prostate disease. He has worked in the media for a very long time, providing protection to famous people including Beyoncé and Weave Dylan - but the shock decision brought his career to a short-term end. Specialists ruled out a medical procedure when tests showed his malignancy had spread and the dad-of-six began to lose confidence.

Regardless, at that point he joined the clinical preliminary examination and began treatment with a drug that is currently expanding the existence of thousands of men around the world. After twelve years, Samuels, from Harrow, north-west London, invited six grandchildren into the world and turned to another profession that brought to light the issues of malignant growth research.

"Because of the late stage when my malignant prostate growth was analyzed, I wouldn't be here today if I wasn't ready to get to clinical training. It was my help," said Samuels, now 66. "This message had to happen. It should now be mandatory to preserve nationality in clinical trials and trials should reflect the ethnic diversity of the population so that we can find better drugs for individuals like me."

Amy Rylance, head of further development thinking at the Prostate Disease UK Foundation, said the Lancet report was "a fitting source of inspiration". She added that medical care frameworks should improve on the perception of those at highest risk: individuals of color and men with a family background of malignant prostate growth or hereditary risk factors such as BRCA varieties.